St. Louis School of Medicine: Experimental Drug Shows Early Promise Against Inherited Form of ALS, Trial Indicates
July 09, 2020
July 09, 2020
ST. LOUIS, Missouri, July 9 -- The Washington University St. Louis School of Medicine issued the following news release:
An experimental drug for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a phase 1/phase 2 clinical trial conducted at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston and other sites around the world and sponsored by the pharmaceutical company Biogen Inc. The trial indicated that th . . .
An experimental drug for a rare, inherited form of amyotrophic lateral sclerosis (ALS) has shown promise in a phase 1/phase 2 clinical trial conducted at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston and other sites around the world and sponsored by the pharmaceutical company Biogen Inc. The trial indicated that th . . .